XXXX plus @entity1206 as induction chemotherapy followed by surgery in the treatment of stage IIIB @entity1149 . Final results of a multicenter phase II study.

@entity1 @entity8 @entity137 @entity390 @entity417 @entity1149 @entity900 @entity391 @entity1206 @entity260 @entity1398 @entity3483
BACKGROUND: The combination of @entity900 and @entity1206 has been shown to be effective in @entity1 with advanced @entity1149 ( @entity1149 ). Based on these data, we planned to treat @entity1 with stage IIIB @entity1149 without @entity3483 and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment. MATERIALS AND METHODS: Thirty @entity1 entered into the study and were treated preoperatively with @entity900 120 mg/m2 given on day 1 and @entity1206 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of @entity1 were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only @entity1 who achieved an objective response underwent surgery. RESULTS: A total of 82 (91.1%) cycles were administered with moderate @entity137 : WHO grade (G) 2 and 3 @entity1398 occurred in 20 (66.6%) @entity1 , G 3 @entity417 occurred in 4 (13.3%), G 3 @entity390 / @entity391 in 20 (66.6%) and G 1-2 @entity8 in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) @entity1 achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all @entity1 ) and pathological complete resection in 5 (16.6%). No @entity260 were reported. The median survival for all @entity1 was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive @entity1 was 27 (exact 95% confidence limits, 13 to 33) months. CONCLUSION: The combination of @entity900 and @entity1206 is effective and safe as a neoadjuvant therapy in stage IIIB @entity1149 , showing a high response rate (60%) and amenability to surgery.
